Pulmonary artery aneurysms: Preoperative, intraoperative, and postoperative findings

Berhane M Worku1, Paolo de Angelis1, Matthew E Wingo1

  • 1Department of Cardiothoracic Surgery, Weil Cornell Medicine, New York, New York.

Insights

Surgical repair of large pulmonary artery aneurysms (PAAs) in six patients resulted in 0% operative mortality and symptom improvement. This indicates PAA repair is a safe and effective option for select individuals.

Area of Science:

  • Cardiovascular Surgery
  • Thoracic Surgery
  • Vascular Surgery

Background:

  • Pulmonary artery aneurysms (PAAs) are rare, potentially lethal cardiovascular conditions.
  • PAAs are often associated with congenital heart disorders, infections, vasculitis, pulmonary hypertension, and malignancies.
  • Limited data exists due to the rarity, necessitating case series for treatment insights.

Purpose of the Study:

  • To describe the surgical experience with large PAAs at a single institution.
  • To evaluate the safety and efficacy of surgical PAA repair.
  • To highlight outcomes in patients with pulmonary hypertension.

Main Methods:

  • Retrospective analysis of clinical data for patients undergoing PAA surgery (2009-2017).
  • Surgical repair involved woven Dacron grafts for four patients.
  • Concomitant pulmonary valve procedures were performed in five patients.

Main Results:

  • Six patients with large PAAs (average size 65.0 mm) underwent surgery.
  • Average age at surgery was 59.73 years; 83.3% had hypertension.
  • Zero operative and 30-day mortality was observed, with an average hospital stay of 10.5 days.

Conclusions:

  • Surgical repair of PAAs demonstrated a 0% postoperative mortality rate.
  • All patients experienced symptom improvement following PAA repair.
  • PAA repair is a safe and effective treatment option for carefully selected patients.
Abstract

Related Concept Videos

Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
393
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
584
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
450
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
478
Finding the Center of Gravity01:03

Finding the Center of Gravity

The center of gravity of a body is an imaginary point where the body's total weight is assumed to be concentrated, and the body is perfectly balanced. The center of the mass of a body is a point at which the whole of the mass of the body appears to be concentrated. If the acceleration due to gravity, g, has the same value at all points on a body, its center of gravity is identical to its center of mass. The center of gravity of homogeneous bodies such as a sphere, cube, or rectangular plate...
4.3K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
601